title: Survival after brain metastases from breast cancer in the trastuzumab era.
authors.forename: David G
authors.initials: DG
authors.lastname: Kirsch
authors.forename: Carlos J
authors.initials: CJ
authors.lastname: Ledezma
authors.forename: Christina S
authors.initials: CS
authors.lastname: Mathews
authors.forename: Atul K
authors.initials: AK
authors.lastname: Bhan
authors.forename: Marek
authors.initials: M
authors.lastname: Ancukiewicz
authors.forename: Fred H
authors.initials: FH
authors.lastname: Hochberg
authors.forename: Jay S
authors.initials: JS
authors.lastname: Loeffler
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000556:secondary; D001943:Breast Neoplasms / Q000473:pathology*; D003131:Combined Modality Therapy; D005260:Female; D018734:Genes, erbB-2; D006801:Humans; D008875:Middle Aged; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068878:Trastuzumab